Literature DB >> 23161053

TNFAIP3 gene polymorphisms confer risk for Behcet's disease in a Chinese Han population.

Hong Li1, Qing Liu, Shengping Hou, Liping Du, Qingyun Zhou, Yan Zhou, Aize Kijlstra, Zheng Li, Peizeng Yang.   

Abstract

The tumor necrosis factor alpha-inducible protein 3 (TNFAIP3) gene polymorphisms have recently been reported to be associated with the susceptibility to several immune-related diseases. This study was performed to evaluate the potential association of TNFAIP3 polymorphisms with Behcet's disease (BD) in a Chinese Han population. Five single-nucleotide polymorphisms (SNPs), rs10499194, rs610604, rs7753873, rs5029928, and rs9494885 of TNFAIP3 were genotyped in 722 BD patients and 1,415 healthy controls using a PCR-restriction fragment length polymorphism assay. Allele and genotype frequencies were compared between patients and controls using the χ (2) test. The results showed a significantly increased prevalence of the rs9494885 TC genotype and C allele in BD patients compared with controls (Bonferroni corrected p (p (c)) = 1.83 × 10(-10), odds ratio (OR) [95% CI] 2.03 [1.65-2.49]; p (c) = 8.35 × 10(-10), OR [95% CI] 1.81 [1.51-2.18], respectively).The frequency of the TT genotype and T allele of rs9494885 was markedly lower in BD patients than that in controls (p (c) = 1.23 × 10(-10), OR [95% CI] 0.50 [0.40-0.61]; p (c) = 8.35 × 10(-10), OR [95% CI] 0.55 [0.46-0.66], respectively). For rs10499194, a higher frequency of the CC genotype (p (c) = 0.015, OR [95% CI] 1.96 [1.30-2.97]) and C allele (p (c) = 0.005, OR [95% CI] 1.92 [1.28-2.90]), and a lower frequency of the TC genotype (p (c) = 0.015, OR [95% CI] 0.51 [0.34-0.77]) and T allele (p (c) = 0.005, OR [95% CI] 0.52 [0.35-2.97]) were found in BD patients. Concerning rs7753873, a higher frequency of the AC genotype (p (c) = 0.015, OR [95% CI] 1.49 [1.17-1.91]) and C allele (p (c) = 0.025, OR [95% CI] 1.39 [1.11-1.76]), and a lower frequency of the AA genotype (p (c) = 0.03, OR [95% CI] 0.68 [0.53-0.87]) and A allele (p (c) = 0.025, OR [95% CI] 0.72 [0.57-0.91]) were observed in BD patients. This study identified one strong risk SNP rs9494885 and two weak risk SNPs rs10499194 and rs7753873 of TNFAIP3 in Chinese Han BD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161053     DOI: 10.1007/s00439-012-1250-7

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  49 in total

1.  Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test.

Authors:  A Gül; A H Hajeer; J Worthington; J H Barrett; W E Ollier; A J Silman
Journal:  Arthritis Rheum       Date:  2001-01

2.  STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behçet's disease.

Authors:  Ke Hu; Peizeng Yang; Zhengxuan Jiang; Shengping Hou; Liping Du; Fuzhen Li
Journal:  Hum Immunol       Date:  2010-05-14       Impact factor: 2.850

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity.

Authors:  Rita M Tavares; Emre E Turer; Chih L Liu; Rommel Advincula; Patrizia Scapini; Lesley Rhee; Julio Barrera; Clifford A Lowell; Paul J Utz; Barbara A Malynn; Averil Ma
Journal:  Immunity       Date:  2010-08-12       Impact factor: 31.745

5.  B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice.

Authors:  Yuanyuan Chu; J Christoph Vahl; Dilip Kumar; Klaus Heger; Arianna Bertossi; Edyta Wójtowicz; Valeria Soberon; Dominik Schenten; Brigitte Mack; Miriam Reutelshöfer; Rudi Beyaert; Kerstin Amann; Geert van Loo; Marc Schmidt-Supprian
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

6.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.

Authors:  David L Boone; Emre E Turer; Eric G Lee; Regina-Celeste Ahmad; Matthew T Wheeler; Colleen Tsui; Paula Hurley; Marcia Chien; Sophia Chai; Osamu Hitotsumatsu; Elizabeth McNally; Cecile Pickart; Averil Ma
Journal:  Nat Immunol       Date:  2004-08-29       Impact factor: 25.606

7.  The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals.

Authors:  Osamu Hitotsumatsu; Regina-Celeste Ahmad; Rita Tavares; Min Wang; Dana Philpott; Emre E Turer; Bettina L Lee; Nataliya Shiffin; Rommel Advincula; Barbara A Malynn; Catherine Werts; Averil Ma
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

8.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis.

Authors:  Lars Vereecke; Mozes Sze; Conor Mc Guire; Brecht Rogiers; Yuanyuan Chu; Marc Schmidt-Supprian; Manolis Pasparakis; Rudi Beyaert; Geert van Loo
Journal:  J Exp Med       Date:  2010-06-07       Impact factor: 14.307

9.  Replication study confirms the association between UBAC2 and Behçet's disease in two independent Chinese sets of patients and controls.

Authors:  Shengping Hou; Qinmeng Shu; Zhengxuan Jiang; Yuanyuan Chen; Fuzhen Li; Feilan Chen; Aize Kijlstra; Peizeng Yang
Journal:  Arthritis Res Ther       Date:  2012-03-29       Impact factor: 5.156

10.  Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus.

Authors:  E Y M G Fung; D J Smyth; J M M Howson; J D Cooper; N M Walker; H Stevens; L S Wicker; J A Todd
Journal:  Genes Immun       Date:  2008-12-25       Impact factor: 2.676

View more
  24 in total

Review 1.  Genetic architectures of seropositive and seronegative rheumatic diseases.

Authors:  Yohei Kirino; Elaine F Remmers
Journal:  Nat Rev Rheumatol       Date:  2015-04-28       Impact factor: 20.543

Review 2.  Dermatologic Manifestations of Monogenic Autoinflammatory Diseases.

Authors:  Kyawt Win Shwin; Chyi-Chia Richard Lee; Raphaela Goldbach-Mansky
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 3.  Advances in the genetically complex autoinflammatory diseases.

Authors:  Michael J Ombrello
Journal:  Semin Immunopathol       Date:  2015-06-16       Impact factor: 9.623

4.  The Immunogenetics of Behcet's Disease.

Authors:  Mustafa Anıl Yılmaz; Ümit Türsen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  The Immunogenetics of Vasculitis.

Authors:  Fotini B Karassa; Eleftherios Pelechas; Georgios Zouzos
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.

Authors:  Jevgenia Zilberman-Rudenko; Linda Monaco Shawver; Alex W Wessel; Yongquan Luo; Martin Pelletier; Wanxia Li Tsai; Younglang Lee; Spiridon Vonortas; Laurence Cheng; Jonathan D Ashwell; Jordan S Orange; Richard M Siegel; Eric P Hanson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-22       Impact factor: 11.205

Review 7.  The immunogenetics of Behçet's disease: A comprehensive review.

Authors:  Masaki Takeuchi; Daniel L Kastner; Elaine F Remmers
Journal:  J Autoimmun       Date:  2015-09-05       Impact factor: 7.094

8.  Single nucleotide polymorphism rs5029937 in TNFAIP3 gene is correlated with risk of rheumatoid arthritis.

Authors:  Bahram Pakzad; Farzaneh Yousefisadr; Hadi Karimzadeh; Maryam Mousavi; Elham Noormohamadi; Rasoul Salehi
Journal:  Med J Islam Repub Iran       Date:  2021-03-31

9.  Behçet's Syndrome in a Chinese Pedigree of NLRP3-Associated Autoinflammatory Disease: A Coexistence or Novel Presentation?

Authors:  Jinjing Liu; Xin Yu; Chaoran Li; Yi Wang; Weihong Yu; Min Shen; Wenjie Zheng
Journal:  Front Med (Lausanne)       Date:  2021-06-24

10.  TNFAIP3 gene polymorphisms in a Chinese Han population with Vogt-Koyanagi-Harada syndrome.

Authors:  Hong Li; Qing Liu; Shengping Hou; Liping Du; Qingyun Zhou; Yan Zhou; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.